Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: CLINICAL TRANSLATIONAL RESEARCH
Abstract #CT09

Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis

Presenter: Senxi Du, Student, Keck School of Medicine of University of Southern California

Co-Authors: Theresa Amoloja, Incyte Corporation, Wilmington, DE; Eileen Peng, Regional Cancer Care Associates, East Brunswick, NJ; Marisa Keck, Regional Cancer Care Associates, East Brunswick, NJ; Ellen Ronnen, Regional Cancer Care Associates, East Brunswick, NJ

Background: Myelofibrosis is a heterogeneous myeloproliferative neoplasm in which risk categorization informs prognosis and treatment.1 Ruxolitinib is indicated for the treatment of patients with intermediate- or high-risk myelofibrosis; starting doses are determined by baseline platelet counts,2 including: 20 mg twice daily for >200 × 109/L; 15 mg twice daily for 100-200 × 109/L; and 5 mg twice daily for 50-<100 × 109/L (dose for <50 × 109/L not established).3,4

Objective: To describe the clinical characteristics and real-world dosing patterns of ruxolitinib among patients with myelofibrosis at a community practice.

Methods: This was a retrospective chart review of adults with confirmed intermediate- or high-risk myelofibrosis who received ruxolitinib between January 1, 2015, and June 20, 2019, at a single community hematology/oncology practice, excluding patients who participated in any myelofibrosis-related clinical trial.

Results: Data from 12 eligible patients were included. The median age was 69 years (range, 56-85 years) at myelofibrosis diagnosis (male, 67%; primary myelofibrosis, 50%). According to the Dynamic International Prognostic Scoring System, at diagnosis, 3 patients had high-risk myelofibrosis, 4 intermediate-2 risk, and 5 intermediate-1 risk; 8 patients had JAK2 mutation, 2 patients had no JAK2 mutation, and 2 patients had other unspecified mutations. At ruxolitinib initiation, the platelet counts were >200 × 109/L (N = 8), 100-200 × 109/L (N = 1), and 50 × 109/L (N = 3). Starting doses varied: 20 mg twice daily (N = 3), 20 mg once daily (N = 1), 15 mg twice daily (N = 2), 10 mg twice daily (N = 2), 5 mg twice daily (N = 3), and 5 mg once daily (N = 1). In all, 7 patients continued ruxolitinib therapy through the study period, with a median duration of 37 months; 4 patients continued the same ruxolitinib dose from initiation until the last visit (5 mg twice daily, N = 2; 20 mg twice daily, N = 1) or ruxolitinib discontinuation (20 mg once daily, N = 1); 3 patients had dose increases, and 5 had decreases. The median time to first dose increase was 0.5 months, and to first dose decrease was 3.5 months. Two patients had dose interruptions (at 3 months and 38 months), and both patients reinitiated ruxolitinib therapy within 1 month. Five patients discontinued ruxolitinib after a median of 8 months for the following reasons: adverse event (initiated at 5 mg twice daily despite having platelets <50 × 109/L), undergoing transplant, patient preference, severe chronic anemia after several dose adjustments, and lack of efficacy (initiated at 20 mg once daily instead of the recommended twice daily).

Conclusion: In a small number of patients with myelofibrosis who were managed at a community practice, a variety of ruxolitinib doses were given, including doses not validated by clinical trials (eg, once-daily doses5,6).

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myeloproliferative Neoplasms. Version 1.2020. May 21, 2020. www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed September 2020.
  2. Jakafi (ruxolitinib) tablets, for oral use [prescribing information]. Incyte Corporation; 2020.
  3. Devos T, Selleslag D, Zachée P, Benghiat FS. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology. 2018;23:194-200.
  4. Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leuk Lymphoma. 2014;55:5-6.
  5. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. . 2010;363:1117-1127.
  6. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81.
Related Items
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, COVID-19
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, Oncology Pharmacy Protocols
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Infusion Issues
Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy
Impact of Drug Repository Program in a Rural Oncology Clinic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Oncology Pharmacy Programs
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Chemotherapy, Oncology Pharmacy Programs
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma, Vaccinations
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.